Harmony Biosciences Holdings, Inc.HRMYNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | -9.15% |
| Q3 2025 | 9.58% |
| Q2 2025 | 45.22% |
| Q1 2025 | -0.36% |
| Q4 2024 | 36.55% |
| Q3 2024 | -60.07% |
| Q2 2024 | 186.55% |
| Q1 2024 | -26.78% |
| Q4 2023 | 73.19% |
| Q3 2023 | 16.90% |
| Q2 2023 | 12.64% |
| Q1 2023 | 31.68% |
| Q4 2022 | -75.11% |
| Q3 2022 | 220.08% |
| Q2 2022 | 67.17% |
| Q1 2022 | 1.70% |
| Q4 2021 | -36.53% |
| Q3 2021 | 80.66% |
| Q2 2021 | 38.88% |
| Q1 2021 | -38.59% |
| Q4 2020 | 80.12% |
| Q3 2020 | 1.46% |
| Q2 2020 | 21.51% |
| Q1 2020 | -52.84% |
| Q4 2019 | 67.80% |
| Q3 2019 | -13.16% |
| Q2 2019 | -90.58% |
| Q1 2019 | 0.00% |